Heart Failure Clinical Trial
Official title:
Study to Determine the Safety and Feasibility of Utilizing the CD Leycom Pressure/Conductance Catheter to Determine Optimal LV Pacing Site
It is hypothesized that it is both safe and feasible to use an interventional approach to LV lead placement (placing the LV lead guided by acute hemodynamic measurements), and that the LV lead can be placed in a position that is superior to the initial empiric lateral wall LV lead location in less than 30 minutes without significant risk to patients. The time from RV capture to LV activation correlates with the optimal pacing site based on stroke volume & dP/dt measurements.
Background
Cardiac synchronization therapy (CRT) is recognized as effective adjunctive therapy for
heart failure; however, up to 40% of patients who undergo CRT device placement do not have a
favorable response to therapy and are labeled non-responders. The lateral wall of the left
ventricle (LV) is generally regarded as the optimal site for LV lead placement and some
non-responders with LV leads not on the lateral wall can be converted to responders by
repositioning the LV lead to the lateral wall. However, recent studies indicate that in some
patients LV lead placement at a site other than the lateral wall may result in a better
response to CRT. In such circumstances, empiric lateral wall lead positioning/repositioning
may expose patients to the risks of another invasive procedure (including an increased risk
of infection); in the case of lead repositioning to improve response to CRT the additional
risk is doubled, as there is no certainty that the new position will be superior to the old.
Several investigators have used the acute hemodynamic response to biventricular pacing to
determine the optimal LV lead position. To make these measurements some groups used a Millar
pigtail catheter (Millar Instruments, Houston, Texas) while other groups used real-time
pressure volume loops with a combined pressure-conductance catheter (CD Leycom, Zoetermeer,
the Netherlands). One criticism of this method is that acute hemodynamic measurements may
not correlate to long term response. However, Delnoy et al demonstrated that acute
improvements in LV function as measured by pressure-volume loops during implantation
corresponded to clinical and echocardiographic improvement during follow-up. In addition,
Duckett et al demonstrated that the acute dP/dt response to LV pacing is useful for
predicting which patients are likely to remodel in response to CRT, for both dilated and
ischemic cardiomyopathy.
Despite these observations, few practitioners routinely utilize acute hemodynamic
measurements for LV lead placement at the time of device implantation. Many practitioners
believe targeted LV lead placement is impractical due to the time required to determine
hemodynamic response to CRT and reposition the LV lead, and that venous anatomy, phrenic
nerve pacing, and high pacing thresholds severely limit options for LV lead placement.
Study Hypothesis
It is hypothesized that it is both safe and feasible to use an interventional approach to LV
lead placement (placing the LV lead guided by acute hemodynamic measurements), and that the
LV lead can be placed in a position that is superior to the initial empiric lateral wall LV
lead location in less than 30 minutes without significant risk to patients. The time from RV
capture to LV activation correlates with the optimal pacing site based on stroke volume &
dP/dt measurements.
Study Purpose
The purpose of this study is to determine whether utilizing the CD Leycom
pressure-conductance catheter to measure dP/dt and pressure volume loops at the time of LV
lead implant (whether for the initial CRT implant or revision of an existing system) is both
safe and feasible. It is hoped that the study will determine whether it is possible to use a
patient's hemodynamic response to pacing to locate an LV pacing site that provides better
hemodynamic response to CRT than the empirically selected lateral wall pacing site without
significant patient risk (in terms of radiation exposure, amount of contrast received,
procedure time, potential injury).
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
| Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
| Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
| Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
| Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
| Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
| Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
| Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
| Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
| Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
| Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
| Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
| Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
| Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|